Lung Cancer Patient given Chemotherapy through In Vivo Lung Perfusion with STEEN Solution™

STEEN Solution™ was used for the first time to give localized delivery of a
chemotherapy agent to a patient suffering from metastatic lung sarcoma through
In-Vivo Lung Perfusion (IVLP).  This was also the first time STEEN Solution was
used to perfuse a lung on In-Vivo i.e. on a living patient. The aim of the study
is to prove safety and evaluate the ability to use STEEN Solution™ to improve
isolated tissue therapy.
A leading hospital enrolled their first patient into a clinical trial to provide
chemotherapy to patients suffering from lung sarcomas.  According to the 2016
data from the American Cancer Society, soft tissue sarcomas affect approximately
12,310 people annually in the United States and more than 4,990 Americans will
die each year of this disease.  Of the patients who develop extremity sarcoma,
approximately 20% will have isolated pulmonary metastatic disease at some point
in the course of their disease.  Surgery is the preferred way of treating
pulmonary sarcomas but due to micrometastasis, that cannot be seen, the person
has a greater than 70% risk of pulmonary recurrence after this surgery. The use
of systemic chemotherapy has not been used due to the significant side effects
with unproven benefit. With the use of in-vivo lung perfusion the surgeon can
shut off the lung from the systemic circulation and give the chemotherapy only
to the lung so as not to affect the rest of the body.

“This is a significant step forward in expanding the capability of IVLP in
cancer therapy.  The dosage of chemotherapy given is yet to be determined to
give optimal therapy with reduced side effects but this is the beginning of a
new chapter in cancer therapy”, says Magnus Nilsson, CEO of XVIVO Perfusion.

June 22, 2016
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on June 22, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com